Legend Biotech (LEGN)
(Delayed Data from NSDQ)
$59.67 USD
-0.21 (-0.35%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $59.69 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
LEGN 59.67 -0.21(-0.35%)
Will LEGN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LEGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LEGN
Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid
Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?
LEGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Buy Legend Biotech (LEGN) Ahead of Earnings?
FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
Why Legend Biotech (LEGN) Stock Might be a Great Pick
Other News for LEGN
Johnson & Johnson: Seriously Undervalued At Peak Pessimism
Week In Review: Korea's SK Biopharma Acquires Radiopharmaceutical In $571 Million Deal
Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday
Legend Biotech price target raised by $5 at Scotiabank, here's why
Scotiabank Sticks to Their Buy Rating for Legend Biotech (LEGN)